Tricuspid Version of Abbott’s MitraClip Improves Short-Term Outcomes In TRILUMINATE

Early results of the TRILUMINATE trial presented at the EuroPCR conference will support a CE mark for a version of MitraClip adapted to reduce tricuspid valve regurgitation.

BEIJING, CHINA- JULY 15, 2017: Abbott sign; Abbott Laboratories, founded in 1888, is a health care company that serves worldwide. It has more than 20 billon USD in revenue last year. - Image
• Source: shutterstock.com

More from Clinical Trials

More from R&D